RxDoctor Payments Data

Yolanda Abreu Brito, APRN

Family · Boynton Beach, FLNPI 1275306581

Payments from drug & device makers

$945in general payments, 2019–2025

Across 25 payments — averaging $37.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$201
  • Impulse Dynamics (USA) Inc.$143
  • Medtronic$120
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$118
  • Alnylam Pharmaceuticals Inc.$110
  • Bayer$72
  • plus $181 from 6 others

What the payments were for

  • Food & beverage$945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$945 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$2,843
Medicare patients
23
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$37,451
EntrestoSacubitril/Valsartan22$35,363
XareltoRivaroxaban23$22,284
Ezetimibe23$958
Metoprolol Succinate55$837
Atorvastatin Calcium39$465
ClopidogrelClopidogrel Bisulfate37$381
Nifedipine ErNifedipine12$332
Labetalol Hcl13$323
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$320
Carvedilol42$259
Amlodipine Besylate48$248
Losartan Potassium34$233
Rosuvastatin Calcium22$232
Lisinopril24$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$13$35,36322 claims
Johnson & JohnsonXarelto$35$22,28423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →